NCT01088360Active, not recruiting
Safety Study of Abatacept to Treat Rheumatoid Arthritis (B)
An Observational Cohort to Assess Safety and Outcomes in Patients Treated With Abatacept and Other Anti-Rheumatic Therapies
Source: ClinicalTrials.gov · Last updated 18 Jan 2019
Brief summary (registry, in English)
The purpose of this study is to compare the incidence rates of targeted infections, malignancies and mortality among patients with rheumatoid arthritis who are treated with abatacept and those who are treated with other anti-rheumatic medications.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 20000 (estimated)
- First submitted
- 12 Mar 2010
- Start date
- 31 Mar 2005
- Primary completion date
- 30 Jun 2029
- Lead sponsor
- Bristol-Myers Squibb
- Diseases
- Rheumatoid arthritis
- NCT number
- NCT01088360
What you commit to
- Study type: Observational
- Planned participants: 20000
- From 31 Mar 2005 to the primary completion date, 30 Jun 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- None
Who the study is looking for
- Signed informed consent
- Diagnosis of rheumatoid arthritis
- \> 18 years at index treatment initiation or switch
- Starting treatment with abatacept or new disease-modifying anti-rheumatic drug (including switching or adding) or biologic disease modifying drug.
- Read/write English
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.